Merck & Co has presented additional data from Phase III studies of the investigational, once-daily, oral, two-drug regimen of ...

Shares of Omeros Corp skyrocketed 155% to $10.43 this morning, following the news of an asset purchase agreement with Novo ...

US biotech startup Lila Sciences has closed its series A at $350 million, lifting its total fundraising to $550 million. The ...

Japanese pharma major Astellas Pharma yesterday released disappointing data from the Phase II GLEAM trial investigating ...

UK-based weight loss treatment company Oxford Medical Products is targeting 2027 for the commercial release of its ...

US pharma major Gilead Sciences (Nasdaq: GILD) used the European AIDS Conference in Paris to showcase progress across its HIV ...

Welcome to The Pharma Letter’s real-time coverage of the 2025 European Society of Medical Oncology (ESMO) Congress, taking ...

Omnix Medical, a Jerusalem, Israel-based biopharma tackling drug-resistant infections and developing next-generation ...

US pharma major Pfizer (NYSE: PFE) has reported positive Phase III data that could help validate its $43 billion Seagen ...

Australia’s Biotron has announced the acquisition of unlisted UK company Sedarex Limited, the owner of SedRx - a patented ...

Swiss clinical-stage biotech Alentis Therapeutics today announced the appointment of Dr Mark Pruzanski, as the company’s new ...

Shares of US clinical stage biopharma Candel Therapeutic closed down 10.4% at $5.78 on Tuesday after it revealed it has ...